📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Geron Corporation (GERN)

NASDAQ
Currency in USD
Disclaimer
4.6700
-0.0900(-1.89%)
Closed
After Hours
4.7200+0.0500(+1.0707%)
GERN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 13 days
Fair Value
Day's Range
4.62004.8600
52 wk Range
1.64005.3400
Prev. Close
4.76
Open
4.73
Day's Range
4.62-4.86
52 wk Range
1.64-5.34
Volume
4,254,155
Average Vol. (3m)
11,520,563
1-Year Change
44.14%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
GERN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
7.2143
Upside
+54.4818%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

People Also Watch

12.860
SMR
-7.68%
5.350
WULF
-9.32%
10.230
IREN
-9.15%
13.9400
ZAPP
+1.90%
19.10
NNE
-15.78%

Geron Corporation Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.